Just reading through the latest...with particular attention to the AVERT trial results.
The company has released a fairly rosey interpretation of their trial results but for me there is a big miss with one of the key aims of AVERT!
The trial did NOT show a reduction in the rates of CIN (contrast induced nephropathy), whilst it did support the other 3 claims:
- 15% less dye used
- image quality not compromised
- significant reflux reduction
To me, those are consolation prizes.
I think the big tick for this would have been if they saw reduced rates of CIN, after all that is the whole point of their product!
So in summary, it does use less dye and does not compromise image quality, BUT this has no effect on actually reducing damage to the kidneys from the dye.
Yet they are still ramping up commercialisation and adding 5 more sales reps. hmmm...I'm not convinced
Interesting to see how the market takes this news.
OSP Price at posting:
67.0¢ Sentiment: Buy Disclosure: Held
